Shares of the company fell about 16 percent to $2.95 in
pre-market trade. They closed at $3.50 on Thursday on Nasdaq.On Aug. 1, the company said the FDA placed a hold on two
late-stage trials for the drug, in cystic fibrosis patients with
Pseudomonas lung infections and patients with non-tuberculous
mycobacterial (NTM) lung disease.FDA now requires the company to conduct a mid-stage study in
adult NTM patients to provide efficacy and safety data, and to
further revise the assessment of a rat carcinogenicity study
findings.”Now that we have responses from the FDA with respect to
both clinical holds, we are seeking further inputs from the
agency in order to gain a better understanding of their requests
regarding CF and NTM,” Chief Executive Timothy Whitten said in a
statement.
so, i hate odd future. i haven’t talked about it here before, because i really don’t feel like they need more e-ink...
Filed under: 携帯電話 [http://japanese.engadget.com/category/cellphones/]
![]()
Volkswagen Passat Commercial: The Force
A pint-sized Darth Vader who uses the Force when he discovers the all-new 2012 Passat...
Touareg Women near the city of Agadez in Niger
So like everyone else I heard that you could tether your Wi-Fi only iPad to the iPhone 4...
![]()

This is my interview with Genevieve Schatz, singer of Company of Thieves, at the band’s...
I wasn’t always an Apple fan. I still don’t see myself firmly in one camp or another. I have two Android phones and just the...